When it comes to managing stroke risk, two commonly prescribed medications are Lipitor, a statin used to lower cholesterol levels, and Aspirin, an antiplatelet agent that prevents blood clot formation. According to a review by the American Heart Association [1], both Lipitor and Aspirin are used to reduce the risk of stroke in certain patient populations.

One key difference between the two medications is their mechanism of action. Lipitor, also known as atorvastatin, works by inhibiting the production of cholesterol in the liver, thereby reducing the risk of atherosclerotic plaque formation and subsequent stroke [2]. In contrast, Aspirin prevents blood platelets from aggregating and forming clots, which can lead to a stroke [3].

In terms of dosage and administration, Lipitor is typically taken once daily, with food to enhance bioavailability, whereas Aspirin is usually taken as a daily low-dose tablet, typically 81 mg [4]. This lower dose of Aspirin is used to balance the benefits of reduced clotting risk against the potential risk of bleeding complications.

The benefits of Lipitor in stroke prevention are most pronounced in patients with pre-existing high cholesterol levels or those at risk of atherosclerotic cardiovascular disease [2]. Aspirin, on the other hand, is typically recommended for patients with a history of transient ischemic attack (TIA) or stroke, as well as those at high risk of future stroke due to other factors, such as high blood pressure or diabetes [5].

DrugPatentWatch.com reports that Lipitor (Atorvastatin) patent protection expired in 2011 in the United States, allowing generic versions of the medication to become widely available [6]. In contrast, Aspirin is available generically, which often contributes to the affordability of the medication.

In conclusion, both Lipitor and Aspirin are important tools in the management of stroke risk, but they differ in their mechanisms of action, dosing, and patient indications.

Sources:

[1] American Heart Association. (2019). Heart Attack and Stroke Prevention. Retrieved from https://www.heart.org/en/health-topics/cardiometabolic-risk/heart-attack-and-stroke-prevention

[2] Lipitor (Atorvastatin) Product Label. (2015). Pfizer. Retrieved from https://www.accessdata.fda.gov/drugsatfdadocs/nda/97/020633AtorvastatinTOC.cfm

[3] Aspirin Product Label. (2020). Johnson & Johnson. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/061036s040lbl.pdf

[4] National Heart, Lung, and Blood Institute. (2020). Aspirin for Atherosclerosis Prevention. Retrieved from https://www.nhlbi.nih.gov/health-topics/aspirin-for-atherosclerosis-prevention

[5] Aspirin in the Primary Preven- tion of Atherosclerotic Cardiovascular Disease in Persons with Diabetes. (2019). American Diabetes Association.

[6] DrugPatentWatch.com. Atorvastatin (Atorvastatin) Patent Expired. Retrieved from https://www.drugpatentwatch.com/US/at/orvastatin/US20120115843